Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C

A throwback regimen of sofosbuvir (Sovaldi), ribavirin and pegylated interferon taken for 12 weeks cured 93% of people with hepatitis C virus (HCV) genotype 3 – substantially

Published
4 hours ago
By
Liz Highleyman
Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced

Published
5 hours ago
By
Liz Highleyman
New EASL guidelines prioritise interferon-free hepatitis C treatment

The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment guidelines at the 50th International Liver Congress which took place last

Published
27 April 2015
By
Liz Highleyman
Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C

People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious comorbidity such as

Published
27 April 2015
By
Keith Alcorn
Gilead uses Georgia as free-drug testbed for hepatitis C elimination

Gilead Sciences is seeking to convince governments and multilateral agencies worldwide that hepatitis C can be eliminated with a demonstration project in Georgia offering free drugs to all those who need them.

Published
27 April 2015
From
Reuters
Expanded vaccination and treatment could help eliminate hepatitis B worldwide

While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment

Published
25 April 2015
By
Liz Highleyman
Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients

The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in

Published
25 April 2015
By
Keith Alcorn
Advanced liver damage is common in people with undiagnosed hepatitis C in US survey

Around one in five people with hepatitis C in the United States who do not know of their infection may already have advanced liver damage and be

Published
25 April 2015
By
Keith Alcorn
Grazoprevir / elbasvir highly effective in previously untreated hepatitis C

A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with genotypes 1, 4 or 6 hepatitis C virus (HCV), according

Published
24 April 2015
By
Keith Alcorn
Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease

An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response (SVR) rates of 85-88% for people with genotype

Published
24 April 2015
By
Liz Highleyman
← First12345...164Next →

Filter by country